274 related articles for article (PubMed ID: 24345815)
1. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
[TBL] [Abstract][Full Text] [Related]
2. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
Kosaki K; Tamura K; Sato R; Samejima H; Tanigawara Y; Takahashi T
Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Hashi S; Yano I; Shibata M; Masuda S; Kinoshita M; Matsumoto R; Ikeda A; Takahashi R; Matsubara K
Eur J Clin Pharmacol; 2015 Jan; 71(1):51-8. PubMed ID: 25323806
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
5. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
6. Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.
Tolbert D; Bekersky I; Chu HM; Ette EI
J Clin Pharmacol; 2016 Mar; 56(3):365-74. PubMed ID: 26224203
[TBL] [Abstract][Full Text] [Related]
7. Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Russell GR; Phelps SJ; Shelton CM; Wheless JW
Ther Drug Monit; 2018 Aug; 40(4):452-462. PubMed ID: 29746397
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Nishimura S; Kasai R; Ikeda H; Takayama R; Mogami Y; Yamaguchi T; Terada K; Matsuda K; Inoue Y; Kagawa Y
Ther Drug Monit; 2013 Jun; 35(3):305-12. PubMed ID: 23666564
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
Jullien V; Chhun S; Rey E; Dulac O; Tod M; Chiron C; Pons G
Clin Pharmacokinet; 2015 May; 54(5):527-36. PubMed ID: 25503589
[TBL] [Abstract][Full Text] [Related]
10. Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Yamamoto Y; Takahashi Y; Imai K; Mogami Y; Matsuda K; Nakai M; Kagawa Y; Inoue Y
Epilepsy Behav; 2014 May; 34():124-6. PubMed ID: 24742983
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Burns ML; Baftiu A; Opdal MS; Johannessen SI; Landmark CJ
Ther Drug Monit; 2016 Jun; 38(3):350-7. PubMed ID: 26751267
[TBL] [Abstract][Full Text] [Related]
12. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Contin M; Riva R; Albani F; Baruzzi AA
Ther Drug Monit; 1999 Dec; 21(6):604-8. PubMed ID: 10604819
[TBL] [Abstract][Full Text] [Related]
13. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
14. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.
Contin M; Sangiorgi S; Riva R; Parmeggiani A; Albani F; Baruzzi A
Ther Drug Monit; 2002 Dec; 24(6):737-41. PubMed ID: 12451290
[TBL] [Abstract][Full Text] [Related]
15. A Thorough QT/QTc Study of Clobazam in Healthy Volunteers.
Tolbert D; Gordon J; Harris S; Walzer M; Bekersky I; Reid S
Clin Ther; 2017 Oct; 39(10):2073-2086. PubMed ID: 28958437
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S
Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060
[TBL] [Abstract][Full Text] [Related]
17. Interactions of clobazam with conventional antiepileptics in children.
Theis JG; Koren G; Daneman R; Sherwin AL; Menzano E; Cortez M; Hwang P
J Child Neurol; 1997 Apr; 12(3):208-13. PubMed ID: 9130097
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.
Yamamoto Y; Takahashi Y; Imai K; Takahashi M; Nakai M; Inoue Y; Kagawa Y
Eur J Clin Pharmacol; 2014 Oct; 70(10):1203-10. PubMed ID: 25048408
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
Seo T; Nagata R; Ishitsu T; Murata T; Takaishi C; Hori M; Nakagawa K
Pharmacogenomics; 2008 May; 9(5):527-37. PubMed ID: 18466100
[TBL] [Abstract][Full Text] [Related]
20. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
